SCHEMBL23769637

SCHEMBL23769637

O=C(O)c1cnn(Cc2ccc(N3CC4(CC4)C3)nc2Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 9/20 0.47
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
EGLN1 Q9GZT9 4/20 0.37
LMNA P02545 1/20 0.36
PKM P14618 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BTK Q06187 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23769198 0.87 KLKB1 (0.49) KLKB1HSD17B10L3MBTL1POLBTDP1
SCHEMBL21713003 0.87 KLKB1 (0.60) KLKB1
SCHEMBL29906644 0.87 KLKB1 (0.60) KLKB1
SCHEMBL23769195 0.87 KLKB1 (0.47) KLKB1HSD17B10L3MBTL1POLBTDP1
SCHEMBL23769171 0.86 KLKB1 (0.47) KLKB1HSD17B10L3MBTL1POLBTDP1
SCHEMBL29976929 0.86 KLKB1 (0.47) KLKB1POLB
SCHEMBL23753974 0.86 KLKB1 (0.47) KLKB1POLB
SCHEMBL23769626 0.85 KLKB1 (0.48) KLKB1HSD17B10L3MBTL1POLBTDP1
SCHEMBL23754273 0.84 KLKB1 (0.46) KLKB1HSD17B10L3MBTL1POLBTDP1
SCHEMBL30140695 0.83 KLKB1 (0.56) KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
WO-2021160718-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 KLKB1 1/4885HSD17B10 725/4885L3MBTL1 4462/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 KLKB1 1/4885HSD17B10 725/4885L3MBTL1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.